What is Arcadia Biosciences, Inc.'s earnings per share (EPS)?

Arcadia Biosciences, Inc. (RKDA) reported diluted earnings per share of -$1.71 for fiscal year 2025. This represents a 66.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Arcadia Biosciences, Inc. (RKDA) Financials

RKDA

FY2025 annual

Revenue $4.9M -3.7% YoY

Net Income -$2.3M +66.8% YoY

EPS (Diluted) -$1.71 +66.9% YoY

Free Cash Flow -$4.7M +51.3% YoY

Market Cap $484K as of Oct 14, 2026

Price / Sales 0.1x on $4.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.8x on $633K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RKDA SEC filings page.

Arcadia Biosciences, Inc. (RKDA) reported $4.9M in revenue for fiscal year 2025, down 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RKDA FY2025 2026-10-04

Arcadia narrows losses mainly through overhead cuts, while shrinking revenue and recurring cash consumption still define how the business operates.

Margin improvement is cost-led, not volume-led: revenue stayed roughly flat from FY2023 through FY2025 while gross margin narrowed from 51.2% to 36.2%. Over the same period, SG&A fell from $8.2M to $7.0M, allowing operating losses to narrow even though each sales dollar generated less gross profit.

The cash conversion gap remains important: FY2025 net loss was $2.3M while operating cash flow was -$4.7M; free cash flow matched operating cash flow because capital spending was negligible. This means reported earnings understated the cash resources consumed by operations, rather than losses being purely accounting-driven.

The operating base is contracting: total assets fell from $19.7M in FY2023 to $6.5M in FY2025. Reported liquidity equaled 11.7 months of the latest annual outflow, while the current ratio declined and debt-to-equity was lower in FY2025 than FY2024, indicating a smaller but less debt-intensive balance sheet.

Financial Health Signals

Financial Health Score 45/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Arcadia Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Arcadia Biosciences, Inc. held $4.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $4.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Arcadia Biosciences, Inc. scores 33/100 among other emerging companies.

Dilution

Arcadia Biosciences, Inc. had 2M shares outstanding at the end of fiscal year 2025, against 1M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Arcadia Biosciences, Inc. scores 33/100 among other emerging companies.

R&D Intensity

Arcadia Biosciences, Inc. spent $9K on research and development in fiscal year 2025, which was 0.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Arcadia Biosciences, Inc. scores 4/100 among other emerging companies.

Revenue Progress

Arcadia Biosciences, Inc. reported revenue of $4.9M in fiscal year 2025, against $5.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Arcadia Biosciences, Inc. scores 49/100 among other emerging companies.

Burn Trend

Arcadia Biosciences, Inc.'s operations used $4.7M of cash in fiscal year 2025, against $9.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Arcadia Biosciences, Inc. scores 80/100 among other emerging companies.

Balance Sheet

Arcadia Biosciences, Inc.'s cash, cash equivalents and investments came to $4.6M at the end of fiscal year 2025, against $2.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Arcadia Biosciences, Inc. scores 73/100 among other emerging companies.

Altman Z-Score Distress

-59.75

Arcadia Biosciences, Inc. scores -59.75, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($484K) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Arcadia Biosciences, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Arcadia Biosciences, Inc. reported a net loss of $2.3M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Arcadia Biosciences, Inc. reported an operating loss of $2.5M against $221K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4M

YoY-0.8%

QoQ+31.2%

Arcadia Biosciences, Inc. generated $1.4M in revenue in Q2 2026. This represents a decrease of 0.8% from the same quarter a year earlier. Against the prior quarter it is up 31.2%.

EBITDA

-$496K

YoY-2.1%

QoQ+35.7%

Arcadia Biosciences, Inc.'s EBITDA was -$496K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.1% from the same quarter a year earlier. Against the prior quarter it is up 35.7%.

Net Income

-$6.3M

YoY-40.6%

QoQ-42.9%

Arcadia Biosciences, Inc. reported -$6.3M in net income in Q2 2026. This represents a decrease of 40.6% from the same quarter a year earlier. Against the prior quarter it is down 42.9%.

EPS (Diluted)

-$2.09

QoQ+0.9%

Arcadia Biosciences, Inc. earned -$2.09 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 0.9%.

Cash & Balance Sheet

Cash & Debt

$4.2M

YoY+203.6%

QoQ+337.9%

5Y CAGR-37.5%

10Y CAGR-17.1%

Arcadia Biosciences, Inc. held $4.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+17.1%

5Y CAGR-35.8%

10Y CAGR-25.3%

Arcadia Biosciences, Inc. had 2M shares outstanding in Q2 2026. Against the prior quarter it is up 17.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

43.7%

YoY+0.4pp

QoQ+7.4pp

Arcadia Biosciences, Inc.'s gross margin was 43.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.4 percentage points.

Operating Margin

-34.4%

YoY+0.1pp

QoQ+36.5pp

Arcadia Biosciences, Inc.'s operating margin was -34.4% in Q2 2026, reflecting core business profitability. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 36.5 percentage points.

Return on Equity

-989.9%

YoY-891.5pp

QoQ-837.9pp

Arcadia Biosciences, Inc.'s ROE was -989.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 891.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 837.9 percentage points.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

YoY-100.0%

Arcadia Biosciences, Inc. reported no research and development spending in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

RKDA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RKDA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$4.7M	$4.9M-3.7%	$5.0M+13.3%	$4.5M-40.0%	$7.4M+9.4%	$6.8M-15.6%	$8.0M+587.3%	$1.2M-20.2%	$1.5M-63.6%	$4.0M+26.3%	$3.2M-41.1%	$5.4M-22.5%	$7.0M
Cost of Revenue	$3.1M	$3.1M+4.6%	$3.0M+36.3%	$2.2M-64.4%	$6.1M-29.9%	$8.7M+67.5%	$5.2M	N/A	N/A	$283K-68.4%	$895K+0.3%	$892K-55.3%	$2.0M
Gross Profit	$1.6M	$1.8M-15.5%	$2.1M-8.7%	$2.3M+73.1%	$1.3M+168.3%	-$1.9M-168.0%	$2.8M	N/A	N/A	$3.7M+63.2%	$2.3M-49.3%	$4.5M-9.3%	$5.0M
R&D Expenses	N/A	$9K-83.0%	$53K-17.2%	$64K-95.8%	$1.5M-61.2%	$3.9M-51.1%	$8.0M+12.1%	$7.1M+17.0%	$6.1M-18.1%	$7.4M-14.5%	$8.7M-3.4%	$9.0M-10.4%	$10.0M
SG&A Expenses	$5.4M	$7.0M-27.4%	$9.6M+17.1%	$8.2M-45.2%	$15.0M-34.4%	$22.9M+39.3%	$16.5M+21.4%	$13.6M+16.9%	$11.6M+8.9%	$10.7M-13.1%	$12.3M+10.2%	$11.1M+9.8%	$10.1M
Operating Income	-$3.8M	-$2.5M+31.5%	-$3.6M+40.2%	-$6.1M+56.4%	-$14.0M+60.6%	-$35.5M-178.0%	-$12.8M+34.1%	-$19.4M-14.9%	-$16.9M-17.8%	-$14.3M+23.1%	-$18.6M-19.6%	-$15.6M-2.7%	-$15.2M
EBITDA	N/A	-$2.5M+31.3%	-$3.6M+40.1%	-$6.0M+55.7%	-$13.5M+60.8%	-$34.5M-184.6%	-$12.1M+36.9%	-$19.2M-14.8%	-$16.7M-19.1%	-$14.0M+23.4%	-$18.3M-20.0%	-$15.3M-3.2%	-$14.8M
Interest Expense	$12K	$221K-71.7%	$782K+12.5%	$695K+140.5%	$289K+1345.0%	$20K-57.4%	$47K+840.0%	$5K	N/A	$747K-43.4%	$1.3M-50.4%	$2.7M+90.7%	$1.4M
Income Tax	N/A	$8K0.0%	$8K0.0%	$8K-42.9%	$14K+600.0%	$2K+101.6%	-$124K-6300.0%	$2K-80.0%	$10K-61.5%	$26K+4.0%	$25K-3.8%	$26K-90.1%	$263K
Net Income	-$11.1M	-$2.3M+66.8%	-$7.0M+49.7%	-$14.0M+9.0%	-$15.4M-4.9%	-$14.7M-214.9%	-$4.7M+83.8%	-$28.8M-113.7%	-$13.5M+14.2%	-$15.7M+20.0%	-$19.6M-9.3%	-$18.0M+2.1%	-$18.3M
EPS (Basic)	N/A	-$1.71+66.9%	-$5.17+54.2%	-$11.29+56.0%	-$25.65+6.9%	-$27.56	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.71+66.9%	-$5.17+54.2%	-$11.29	-$25.65	-$27.56	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1M+0.3%	1M+10.2%	1M	599,389	532,016	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.4M-0.8%	$1.1M-8.3%	$901K-25.8%	$1.3M-15.3%	$1.5M+11.4%	$1.2M+21.6%	$1.2M+93.8%	$1.5M+18.4%
Cost of Revenue	$812K-1.5%	$700K+2.6%	$708K-14.4%	$884K-14.3%	$824K+30.2%	$682K+44.8%	$827K+4494.4%	$1.0M+26.2%
Gross Profit	$631K0.0%	$400K-22.8%	$193K-50.3%	$418K-17.2%	$631K-6.2%	$518K+0.4%	$388K-36.3%	$505K+5.2%
R&D Expenses	$0-100.0%	N/A	$0-100.0%	$0-100.0%	$9K-10.0%	$0-100.0%	$13K-96.1%	$24K+60.0%
SG&A Expenses	$1.1M-46.9%	$1.2M-32.2%	$1.6M-40.9%	$1.6M-29.9%	$2.1M-20.9%	$1.7M-15.7%	$2.7M+1069.6%	$2.2M+20.4%
Operating Income	-$496K+1.0%	-$779K-247.0%	-$1.4M+39.6%	-$1.2M+34.5%	-$501K-125.3%	$530K+133.4%	-$2.3M-470.1%	-$1.8M-26.0%
EBITDA	-$496K-2.1%	-$771K-242.0%	-$1.4M+40.1%	-$1.1M+34.4%	-$486K-124.3%	$543K+135.3%	-$2.3M-527.0%	-$1.8M-34.0%
Interest Expense	$2K-77.8%	$5K-97.6%	-$2K-100.6%	$7K-97.0%	$9K-94.0%	$207K+360.0%	$354K+125.5%	$233K+75.2%
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$6.3M-40.6%	-$4.4M-268.7%	-$1.3M+67.1%	$856K+153.1%	-$4.5M-520.2%	$2.6M+207.3%	-$4.1M-42.2%	-$1.6M+37.2%
EPS (Basic)	-$2.09+35.9%	-$2.11-211.1%	-$0.98+67.2%	$0.63+153.4%	-$3.26-517.9%	$1.90+206.7%	-$2.99-51.0%	-$1.18+37.6%
EPS (Diluted)	-$2.09	-$2.11	-$0.98+67.2%	$0.62+152.5%	-$3.26-517.9%	$1.90+206.7%	-$2.99-51.0%	-$1.18+37.6%
Diluted Shares (Avg)	3M	2M	N/A	1M+0.6%	1M+0.3%	1M+0.3%	N/A	1M+0.3%

RKDA Balance Sheet

RKDA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$6.5M-51.6%	$13.5M-31.4%	$19.7M-31.9%	$28.9M-34.1%	$43.9M-7.2%	$47.3M+45.4%	$32.6M+35.6%	$24.0M+45.0%	$16.6M-70.7%	$56.6M-23.8%	$74.2M+198.3%	$24.9M
Current Assets	$6.4M-31.2%	$9.2M-38.3%	$15.0M-41.1%	$25.4M-28.2%	$35.4M+11.6%	$31.7M+11.4%	$28.4M+24.3%	$22.9M+52.0%	$15.0M-71.2%	$52.2M+0.4%	$52.0M+178.2%	$18.7M
Cash & Equivalents	$259K-93.9%	$4.2M-34.9%	$6.5M-68.4%	$20.6M-28.0%	$28.7M+104.3%	$14.0M+66.8%	$8.4M-29.8%	$12.0M+31.5%	$9.1M+353.3%	$2.0M-91.6%	$24.0M+44.7%	$16.6M
Short-Term Investments	$4.3M	$0-100.0%	$5.1M	$0	$0-100.0%	$11.6M-31.3%	$16.9M+72.2%	$9.8M+152.1%	$3.9M-92.0%	$48.5M+84.8%	$26.3M	$0
Inventory	$1.2M+34.1%	$904K+8.0%	$837K-63.9%	$2.3M-47.6%	$4.4M+16.3%	$3.8M+112.5%	$1.8M+891.2%	$181K-21.0%	$229K-9.1%	$252K-14.3%	$294K-30.7%	$424K
Accounts Receivable	N/A	N/A	N/A	N/A	$1.4M-2.6%	$1.4M+133.6%	$602K+264.8%	$165K-86.6%	$1.2M+252.7%	$349K-50.6%	$706K-32.2%	$1.0M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$2.5M-87.4%	$19.7M	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	$408K	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-67.0%	$7.3M+4.2%	$7.0M-12.7%	$8.0M-36.9%	$12.7M-32.3%	$18.8M-22.5%	$24.2M+116.3%	$11.2M+30.9%	$8.6M-75.1%	$34.4M+1.1%	$34.0M-69.0%	$109.7M
Current Liabilities	$2.1M-19.7%	$2.6M-28.6%	$3.6M-14.7%	$4.2M-16.5%	$5.0M-20.2%	$6.3M+10.6%	$5.7M+86.9%	$3.1M-13.4%	$3.5M+12.7%	$3.1M-9.3%	$3.5M-69.4%	$11.3M
Non-Current Liabilities	$347K-92.7%	$4.7M+38.7%	$3.4M-10.5%	$3.8M-50.4%	$7.7M-38.5%	$12.5M-32.7%	$18.5M+127.3%	$8.2M+61.9%	$5.0M-83.9%	$31.2M+2.2%	$30.6M+14.2%	$26.8M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$2.1M+1867.3%	$107K	$0	$0-100.0%	$25.1M+0.8%	$24.9M+181.1%	$8.9M
Total Equity	$4.1M-33.5%	$6.2M-51.5%	$12.8M-38.9%	$21.0M-32.4%	$31.1M+12.1%	$27.7M+259.8%	$7.7M-39.9%	$12.8M+60.0%	$8.0M-63.9%	$22.2M-44.8%	$40.2M+147.5%	-$84.8M
Retained Earnings	-$281.2M-0.8%	-$278.9M-2.6%	-$271.8M-5.4%	-$257.9M-13.9%	-$226.5M-6.9%	-$211.8M-2.2%	-$207.2M-16.1%	-$178.4M-6.6%	-$167.3M-10.4%	-$151.6M-14.9%	-$131.9M-15.8%	-$114.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.9M-24.3%	$5.3M-59.0%	$6.5M-51.6%	$8.6M-43.7%	$7.8M-55.2%	$13.0M-19.0%	$13.5M-31.4%	$15.2M-35.1%
Current Assets	$5.7M-24.3%	$5.2M-41.6%	$6.4M-31.2%	$8.4M-21.7%	$7.6M-39.0%	$8.8M-24.0%	$9.2M-38.3%	$10.7M-46.5%
Cash & Equivalents	$4.2M+203.6%	$954K-69.8%	$259K-93.9%	$1.1M-71.5%	$1.4M-75.0%	$3.2M-4.8%	$4.2M-34.9%	$3.9M-62.9%
Short-Term Investments	$0-100.0%	$2.8M	$4.3M	$4.8M+80.5%	$3.1M+17.8%	$0-100.0%	$0-100.0%	$2.6M-48.1%
Inventory	$930K-37.5%	$840K-34.6%	$1.2M+34.1%	$1.5M+74.5%	$1.5M+52.2%	$1.3M-29.8%	$904K+8.0%	$835K-68.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.3M+61.6%	$2.4M-40.3%	$2.4M-67.0%	$3.1M-38.3%	$3.3M-43.9%	$4.1M-26.6%	$7.3M+4.2%	$5.1M-36.9%
Current Liabilities	$1.6M-10.5%	$1.4M-38.4%	$2.1M-19.7%	$2.3M-1.8%	$1.8M-31.8%	$2.2M-23.0%	$2.6M-28.6%	$2.3M-40.1%
Non-Current Liabilities	$3.6M+155.2%	$1.1M-42.6%	$347K-92.7%	$856K-69.0%	$1.4M-54.4%	$1.9M-30.4%	$4.7M+38.7%	$2.8M-33.9%
Total Equity	$633K-86.0%	$2.9M-67.6%	$4.1M-33.5%	$5.4M-47.1%	$4.5M-61.3%	$8.9M-16.2%	$6.2M-51.5%	$10.3M-33.8%
Retained Earnings	-$291.9M-4.0%	-$285.6M-3.4%	-$281.2M-0.8%	-$279.9M-1.8%	-$280.7M-2.8%	-$276.3M-0.7%	-$278.9M-2.6%	-$274.8M-2.2%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

RKDA Cash Flow Statement

RKDA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$2.5M	-$4.7M+51.2%	-$9.6M+37.1%	-$15.3M-9.4%	-$14.0M+46.0%	-$25.9M+14.4%	-$30.2M-75.7%	-$17.2M-26.2%	-$13.6M+2.4%	-$14.0M+18.1%	-$17.1M-12.9%	-$15.1M-2.2%	-$14.8M
Depreciation & Amortization	N/A	$32K-44.8%	$58K-47.7%	$111K-76.8%	$479K-54.2%	$1.0M+57.9%	$662K+241.2%	$194K+26.0%	$154K-44.8%	$279K-8.2%	$304K+3.4%	$294K-17.9%	$358K
Stock-Based Compensation	N/A	$234K-54.3%	$512K-28.6%	$717K-35.2%	$1.1M-28.2%	$1.5M-24.5%	$2.0M-10.7%	$2.3M+47.5%	$1.6M+5.2%	$1.5M+39.2%	$1.1M-23.9%	$1.4M+42.6%	$976K
Capital Expenditures	N/A	$0-100.0%	$16K+220.0%	$5K-93.1%	$72K-92.9%	$1.0M-56.9%	$2.3M+58.1%	$1.5M+490.8%	$250K+216.5%	$79K-65.8%	$231K+53.0%	$151K+2.0%	$148K
Free Cash Flow	N/A	-$4.7M+51.3%	-$9.6M+37.0%	-$15.3M-8.9%	-$14.0M+47.7%	-$26.9M+17.4%	-$32.6M-74.3%	-$18.7M-34.5%	-$13.9M+1.2%	-$14.0M+18.8%	-$17.3M-13.3%	-$15.3M-2.2%	-$14.9M
Investing Cash Flow	$0	$750K-89.8%	$7.3M+269.0%	-$4.3M-406.6%	$1.4M-91.5%	$16.6M-3.9%	$17.3M+306.5%	-$8.4M-40.1%	-$6.0M-112.7%	$47.2M	N/A	N/A	N/A
Financing Cash Flow	$5.3M	$6K-33.3%	$9K-99.8%	$5.5M+22.0%	$4.5M-79.4%	$21.9M+6.5%	$20.6M-6.5%	$22.0M-2.2%	$22.5M+186.1%	-$26.1M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$319K+84.3%	-$1.1M+30.8%	-$822K+62.8%	-$257K+85.3%	-$2.0M+17.2%	-$1.6M+50.5%	-$2.2M+46.7%	-$1.8M+39.3%
Depreciation & Amortization	$0-100.0%	$8K-38.5%	$2K+105.9%	$2K-71.4%	$15K-11.8%	$13K-74.5%	-$34K+70.7%	$7K-92.1%
Stock-Based Compensation	$14K-83.7%	$15K-80.8%	N/A	$53K-65.8%	$86K-15.7%	$78K-43.5%	N/A	$155K-4.3%
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$0-100.0%	$0	$0
Free Cash Flow	N/A	N/A	-$822K+62.8%	-$257K+85.3%	-$2.0M+17.3%	-$1.6M+50.7%	-$2.2M+46.7%	-$1.8M+39.3%
Investing Cash Flow	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$250K-94.6%	$500K+12400.0%	$2.5M+4736.5%	$180K+3500.0%
Financing Cash Flow	$3.5M	$1.8M+35780.0%	$0	$1K-75.0%	$0	$5K0.0%	$0	$4K-42.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RKDA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RKDA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	36.2%-5.0pp	41.3%-9.9pp	51.2%+33.4pp	17.8%+46.2pp	-28.4%-63.7pp	35.3%	N/A	N/A	93.0%+21.0pp	71.9%-11.6pp	83.5%+12.1pp	71.4%
Operating Margin	-51.5%+20.9pp	-72.3%	-137.0%	-188.8%	-524.0%	-159.1%	-1657.9%	-1152.3%	-355.6%	-584.1%	-287.5%	-217.0%
Net Margin	-48.1%	-139.5%	-314.0%	-207.3%	-216.2%	-57.9%	-2464.1%	-920.8%	-390.1%	-615.6%	-331.7%	-262.7%
Return on Equity	-56.5%+56.6pp	-113.1%-4.2pp	-108.9%-35.8pp	-73.1%-25.9pp	-47.1%-30.4pp	-16.8%+357.1pp	-373.9%-268.7pp	-105.2%+91.0pp	-196.2%-107.8pp	-88.4%-43.8pp	-44.6%	N/A
Return on Assets	-35.7%+16.3pp	-52.1%+18.9pp	-71.0%-17.8pp	-53.2%-19.8pp	-33.4%-23.5pp	-9.8%+78.6pp	-88.4%-32.3pp	-56.1%+38.7pp	-94.8%-60.1pp	-34.7%-10.5pp	-24.2%+49.5pp	-73.7%
Current Ratio	3.09-0.5x	3.61-0.6x	4.17-1.9x	6.03-1.0x	7.02+2.0x	5.020.0x	4.98-2.5x	7.49+3.2x	4.27-12.4x	16.69+1.6x	15.08+13.4x	1.66
Debt-to-Equity	0.58-0.6x	1.17+0.6x	0.55+0.2x	0.38+0.4x	0.00-0.1x	0.08+0.1x	0.010.0x	0.000.0x	0.00-1.1x	1.13+0.5x	0.62	N/A
Asset Turnover	0.74+0.4x	0.37+0.1x	0.230.0x	0.26+0.1x	0.150.0x	0.17+0.1x	0.040.0x	0.06-0.2x	0.24+0.2x	0.060.0x	0.07-0.2x	0.28
FCF Margin	-96.8%	-191.1%	-343.5%	-189.4%	-396.4%	-405.2%	-1597.5%	-948.2%	-348.8%	-542.2%	-281.9%	-213.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	43.7%+0.4pp	36.4%-6.8pp	21.4%-10.5pp	32.1%-0.8pp	43.4%-8.2pp	43.2%-9.1pp	31.9%-65.2pp	32.9%-4.1pp
Operating Margin	-34.4%+0.1pp	-70.8%-115.0pp	-152.8%	-88.5%	-34.4%	44.2%	-187.7%	-114.5%
Net Margin	-434.2%	-398.6%	-148.3%	65.8%	-306.4%	216.6%	-334.5%	-104.9%
Return on Equity	-989.9%-891.5pp	-152.0%-181.2pp	-32.3%+33.0pp	15.7%+31.4pp	-98.4%-107.4pp	29.2%+52.0pp	-65.3%-43.0pp	-15.7%+0.9pp
Return on Assets	-106.3%-49.1pp	-82.4%-102.4pp	-20.4%+9.7pp	10.0%+20.6pp	-57.2%-63.4pp	20.0%+35.1pp	-30.1%-15.6pp	-10.6%+0.4pp
Current Ratio	3.49-0.6x	3.79-0.2x	3.09-0.5x	3.67-0.9x	4.12-0.5x	3.99-0.1x	3.61-0.6x	4.60-0.5x
Debt-to-Equity	8.31+7.6x	0.85+0.4x	0.58-0.6x	0.58+0.1x	0.72+0.2x	0.46-0.1x	1.17+0.6x	0.490.0x
Asset Turnover	0.24+0.1x	0.21+0.1x	0.140.0x	0.15+0.1x	0.19+0.1x	0.090.0x	0.09+0.1x	0.100.0x
FCF Margin	N/A	N/A	-91.2%	-19.7%	-139.7%	-132.3%	-181.8%	-114.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Arcadia Biosciences, Inc. RKDA	FY2025	$4.9M	-$2.3M	-48.1%	$484K	45/100
Healthy Choice Wellness Corp. HCWC	FY2025	$78.2M	-$3.9M	-5.0%	$10.5M	43/100
Farmmi, Inc. FAMI	FY2025	$28.0M	-$53.1M	N/A	$4.2M	51/100
Natural Alternatives International Inc. NAII	FY2026	$142.5M	-$20.7M	-14.5%	$7.6M	22/100
Steakholder Foods Ltd. STKH	FY2025	N/A	-$11.2M	N/A	$620K	—

Where Arcadia Biosciences, Inc. Ranks

Frequently Asked Questions

What is Arcadia Biosciences, Inc.'s annual revenue?

Arcadia Biosciences, Inc. (RKDA) reported $4.9M in total revenue for fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Arcadia Biosciences, Inc.'s revenue growing?

Arcadia Biosciences, Inc. (RKDA) revenue declined by 3.7% year-over-year, from $5.0M to $4.9M in fiscal year 2025.

Is Arcadia Biosciences, Inc. profitable?

No, Arcadia Biosciences, Inc. (RKDA) reported a net income of -$2.3M in fiscal year 2025, with a net profit margin of -48.1%.

What is Arcadia Biosciences, Inc.'s EBITDA?

Arcadia Biosciences, Inc. (RKDA) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Arcadia Biosciences, Inc.'s gross margin?

Arcadia Biosciences, Inc. (RKDA) had a gross margin of 36.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Arcadia Biosciences, Inc.'s operating margin?

Arcadia Biosciences, Inc. (RKDA) had an operating margin of -51.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Arcadia Biosciences, Inc.'s net profit margin?

Arcadia Biosciences, Inc. (RKDA) had a net profit margin of -48.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Arcadia Biosciences, Inc.'s return on equity (ROE)?

Arcadia Biosciences, Inc. (RKDA) has a return on equity of -56.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Arcadia Biosciences, Inc.'s free cash flow?

Arcadia Biosciences, Inc. (RKDA) recorded an outflow of $4.7M in free cash flow during fiscal year 2025. This represents a 51.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Arcadia Biosciences, Inc.'s operating cash flow?

Arcadia Biosciences, Inc. (RKDA) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Arcadia Biosciences, Inc.'s total assets?

Arcadia Biosciences, Inc. (RKDA) had $6.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Arcadia Biosciences, Inc.'s capital expenditures?

Arcadia Biosciences, Inc. (RKDA) reported no capital expenditure during fiscal year 2025.

How much does Arcadia Biosciences, Inc. spend on research and development?

Arcadia Biosciences, Inc. (RKDA) invested $9K in research and development during fiscal year 2025.

How many shares does Arcadia Biosciences, Inc. have outstanding?

Arcadia Biosciences, Inc. (RKDA) had 2M shares outstanding as of fiscal year 2025.

What is Arcadia Biosciences, Inc.'s current ratio?

Arcadia Biosciences, Inc. (RKDA) had a current ratio of 3.09 as of fiscal year 2025, which is generally considered healthy.

What is Arcadia Biosciences, Inc.'s debt-to-equity ratio?

Arcadia Biosciences, Inc. (RKDA) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Arcadia Biosciences, Inc.'s return on assets (ROA)?

Arcadia Biosciences, Inc. (RKDA) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Arcadia Biosciences, Inc.'s P/E ratio?

Arcadia Biosciences, Inc. (RKDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $484K as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Arcadia Biosciences, Inc.'s price-to-sales ratio?

Arcadia Biosciences, Inc. (RKDA) trades at 0.1x sales, its market capitalization divided by revenue of $4.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $484K as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Arcadia Biosciences, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Arcadia Biosciences, Inc. (RKDA) held $4.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Arcadia Biosciences, Inc.'s Altman Z-Score?

Arcadia Biosciences, Inc. (RKDA) has an Altman Z-Score of -59.75, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Arcadia Biosciences, Inc.'s Piotroski F-Score?

Arcadia Biosciences, Inc. (RKDA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Arcadia Biosciences, Inc.'s earnings high quality?

Arcadia Biosciences, Inc. (RKDA) reported a net loss of $2.3M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Arcadia Biosciences, Inc. cover its interest payments?

Arcadia Biosciences, Inc. (RKDA) reported an operating loss of $2.5M against $221K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Arcadia Biosciences, Inc.?

Arcadia Biosciences, Inc. (RKDA) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.